Dar Al Fouad (DAF) is a tertiary healthcare brand specialized in cardiology, cardio-thoracic surgery and organ transplantation. Headquartered in Cairo, the company is the second-largest private hospital group in Egypt, operating two hospitals with a combined capacity of 378 beds.
During 2018, DAF started operations at its second Cairo facility, Nasr City Hospital. The new hospital, opened in April, is a state-of-the-art structure accommodating 170 beds and 220 outpatient clinics.
The new extension to the 6th of October University Hospital was also brought fully online to increase total available beds from 145 to 208 – the expansion saw this hospital increase 2018 net revenues by 22%.
DAF’s overall revenues increased by more than 75% compared to a 2015 baseline. EBITDA, or earnings before interest, taxation, depreciation and amortization, doubled compared to the previous year. During 2018, the hospital treated more than 14,000 in-patients and some 180,000 outpatients.
Internally, Dar Al Fouad hired a new CEO to position the company for future growth. Dr Mohamed Mamoun Al Najjar, previously Group CEO of Saudi German Hospitals, joined in November 2018.
Looking to the future
In 2019, Dar Al Fouad will focus on establishing new medical excellence centers, improving the patient experience, and optimizing hospital efficiency through data-driven management. Emphasis will be placed on attracting patients to Nasr City Hospital, and obtaining Joint Commission International (JCI) accreditation for that facility.